Download opinion
Add to my selection
Quote this publication Print

RELENZA (zanamivir)

Influenza
Opinions on drugs - Posted on Jul 01 2020

Reason for request

Discontinuation of reimbursement

  • Key points

Unfavourable opinion for maintenance of reimbursement in the treatment of influenza (for more details, see MA).


Clinical Benefit
Insufficient

the clinical benefit of RELENZA is insufficient to justify its funding by the French national health insurance system in the context of:

  • the curative treatment of influenza in the event of a seasonal epidemic or influenza pandemic.

  • the preventive treatment of influenza in the event of a seasonal epidemic or influenza pandemic.

Documents

English version

Contact Us

Évaluation des médicaments
All our publications